Aptevo Therapeutics Business Update
Aptevo Therapeutics announced operational progress in its next-generation trispecific cancer programs, specifically focusing on optimizing manufacturing scalability for its lead candidate, APVO451. The company expects to initiate Investigational New Drug (IND) enabling studies for APVO451 in the first half of 2027. This update signals the transition of the trispecific platform from molecular design toward clinical development readiness.